Parker Cassidy Email & Phone Number

Arlington, VA, US

San Francisco, CA, US

Cytovale is committed to improving human health by pioneering early detection technologies powered by insightful assessment of immune activation. Comprised of an extraordinary team of life scientists, engineers, clinicians and dreamers, Cytovale intends to accelerate the time it takes to get from triage to life-saving therapies. Learn more about Cytovale.

Irvine, CA, US

Beta Bionics is a medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas in both the single hormone and bi-hormonal configurations. The iLet Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to.

Denver, Colorado, US

Cleerly is creating a new standard of care for screening for and treating coronary artery disease through its AI-enabled software solutions.

Rehovot, Merkaz, IL

Nucleix is applying its ultra sensitive, low cost methylation detection technology to cancer screening.

Santa Clara, California, US

Exo is launching a point of care ultrasound platform (hardware and associated software) to enable widespread use of best in class imaging.

Boston, Massachusetts, US

SeLux Diagnostics has developed a novel diagnostic platform for rapid and comprehensive phenotypic Antibiotic Susceptibility Testing (AST) that lowers healthcare costs and improves health outcomes. The SeLux proprietary system consists of a fully automated instrument, assay approach and learning algorithm.

Richmond Hill, Ontario, CA

QVella's FAST ID platform delivers rapid (<1hr) detection of blood stream infections direct from whole blood.Director: 2015-2021Board Observer: 2021-Present

Advisor, Investor and Director from the time of spinning out from BU through to a strategic sale to Unchained Labs. NanoView Biosciences enables sensitive and efficient detection of exosomes and extracellular vesicles (EVs) and other nanoparticles direct from biological samples.

Boston, MA, US

Bengaluru, Karnataka, IN

Led the commercial strategy development and implementation for a novel oncology histoculture platform to predict patient response and inform therapeutic development. Built the worldwide biopharma commercial strategy and team that drove rapid commercial uptake. Developed and implemented the worldwide clinical strategy centered on evidence development to.

Woburn, MA, US

Board member from Series A funding through to strategic sale to Bio-Techne. Quad's bioprocessing technology enables magnetic bead free T-cell separation and activation for CAR-T therapies.

Boston, MA, US

RA Capital is a healthcare crossover fund based in Boston that invests in development-stage private and public drug, medical device, and diagnostic companies.

Franklin Lakes, New Jersey, US

Reporting to the President, Diabetes Care, I was the General Manager leading an internal innovation from startup (concept) through development, including two human trials, for a Class III medical device intended to be BD's breakthrough entry into an emerging, potential $billion+ category.* Recruited and built a new cross functional team.* Led the.

Franklin Lakes, New Jersey, US

Reporting to the General Manager of BD's $850M Infectious Disease Diagnostics unit, I was the General Manager leading the integration of BD's $275M acquisition of HandyLab.* Launched BD MAX - the first fully automated molecular diagnostic system that enables both batch and on-demands testing - at the time, BD's largest innovation initiative.* Developed.

Franklin Lakes, New Jersey, US

Reporting to the General Manager of BD's Molecular Diagnostics business, I was a central leader in developing and delivering on an integrated instrument and assay portfolio to transform the business into a more comprehensive infectious disease leader.* Managed and mentored a group of core team leaders. * Developed portfolio strategy and resource allocation.

US

Executive in the research and drug discovery tools division of Serologicals, driving >20% annual growth in multiple product categories spanning the Upstate, Chemicon and LINCO brands.Led $65M acquisition of LINCO and subsequent integration.Business leader accountable for $70M in annual revenue.Prior roles include:Sr. Director, Business Segment Management.

East Hartford, CT, US

A select rotational program designed to develop future manufacturing leaders. Completed rotations in Shop Floor Supervision, Manufacturing Engineering and International Supply Chain Management.

Master Of Business Administration (Mba)

Bs, Mechanical Engineering